No changes in anti-JCV antibody status after Natalizumab discontinuation in a large population of Multiple Sclerosis patients

被引：0
|
作者：
Sgarlata, E. [1 ,2 ]
Chisari, C. G. [3 ]
D'Amico, E. [3 ]
Toscano, S. [3 ]
Zanghi, A. [3 ]
Lo Fermo, S. [3 ]
Patti, F. [3 ]
机构：
[1] Sapienza Univ, Dept Human Neurosci, Rome, Italy
[2] Umberto I Hosp, Dept Med, Siracusa, Italy
[3] Univ Catania, Sect Neurosci, Dept GF Ingrassia, Catania, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P658
引用
收藏
页码：325 / 325
页数：1
相关论文
共 50 条
  • [21] Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? No
    Labauge, P.
    REVUE NEUROLOGIQUE, 2017, 173 (10) : 614 - 615
  • [22] Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort
    Dominguez-Mozo, Maria I.
    Rus, Macarena
    Santiago, Jose L.
    Izquierdo, Guillermo
    Casanova, Ignacio
    Galan, Victoria
    Angel Garcia-Martinez, M.
    Arias-Leal, Ana M.
    Garcia-Montojo, Marta
    Perez-Perez, Silvia
    Arroyo, Rafael
    Alvarez-Lafuente, Roberto
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 (02) : 158 - 166
  • [23] Evolution of anti-JCV index with natalizumab treatment for multiple sclerosis: a retrospective, longitudinal study
    Ananthavarathan, P.
    White, D.
    Letissier, S.
    Hassan-Smith, G.
    Kumari, S.
    Mistry, N.
    Woolmore, J.
    Mazibrada, G.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 303 - 303
  • [24] Prevalence of Anti-JCV Antibodies in a Cohort of Natalizumab-Treated Multiple Sclerosis Patients from Italy
    Moiola, Lucia
    Sangalli, Francesca
    Martinelli, Vittorio
    Grimaldi, Luigi Maria
    Bucello, Sebastiano
    Ghezzi, Angelo
    Baroncini, Damiano
    Pace, Amy
    Paes, Dominick
    Subramanyam, Meena
    Comi, Giancarlo
    NEUROLOGY, 2011, 76 (09) : A375 - A375
  • [25] Longitudinal anti-JCV antibody titres increase with natalizumab treatment
    Raffel, J.
    Gafson, A.
    Malik, O.
    Nicholas, R.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 296 - 297
  • [26] Anti-JCV Antibody Prevalence in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-2
    Bozic, Carmen
    Richman, Sandra
    Plavina, Tatiana
    Natarajan, Amy
    Scanlon, James
    Subramanyam, Meena
    Sandrock, Alfred
    Bloomgren, Gary
    NEUROLOGY, 2012, 78
  • [27] Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? YES
    Wiertlewski, S.
    REVUE NEUROLOGIQUE, 2017, 173 (10) : 610 - 613
  • [28] Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy
    Olivier Outteryck
    Jean-Claude Ongagna
    Alain Duhamel
    Hélène Zéphir
    Nicolas Collongues
    Arnaud Lacour
    Marie-Céline Fleury
    Anne-Sophie Berteloot
    Frédéric Blanc
    Marianne Giroux
    Patrick Vermersch
    Jérôme de Sèze
    Journal of Neurology, 2012, 259 : 2293 - 2298
  • [29] Anti-JCV Antibodies Detection and JCV DNA Levels in PBMC, Serum and Urine in a Cohort of Spanish Multiple Sclerosis Patients Treated with Natalizumab
    Inmaculada Dominguez-Mozo, Maria
    Garcia-Montojo, Marta
    De Las Heras, Virginia
    Garcia-Martinez, Angel
    Maria Arias-Leal, Ana
    Casanova, Ignacio
    Arroyo, Rafael
    Alvarez-Lafuente, Roberto
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2013, 8 (05) : 1277 - 1286
  • [30] JCV epidemiology in MS (JEMS)-Epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients-Portuguese data
    da Silva, Ana Martins
    Santos, Maria Ernestina
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2014, 337 (1-2) : 119 - 122
12345